Reply to M. Dhanushkodi

We thankDhanushkodi sincerely for his questions regarding our study, “Cardiovascular Disease Risk Factors:HowRelevant inAfricanMenwithProstate Cancer Receiving Androgen-Deprivation Therapy?” In our facility, the gonadotropin-releasing hormone agonist used is goserelin. The dose administered is 3.6 mg every 28 days subcutaneously until the prostate-specific antigen (PSA) level is 0 ng/mL. Then the patient is given a drug holiday and put under observation. Treatment is restarted if relapse occurs. The treatment-naı̈ve groups were younger than the treatedpatients,whichwouldbeexpected, because the treated patients have had the disease for longer. There was no difference in the ages of those who underwent orchiectomy and those on hormonal manipulation.